TriangleNCT01772004 · OUTCOME
Dose Expansion Cohort: Number of Participants With Immune Related Best Overall Response (irBOR) According to Modified Immune-Related Response Criteria (irRC)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- Dose Expansion: Baseline up to Day 2023
What was measured
irBOR defined as best response of any of immune related complete response (irCR), immune related partial response (irPR), immune related stable disease (irSD) and immune related progressive disease (irPD) recorded from baseline until immune related disease progression and determined according to modified irRC per investigator assessment. irCR: Complete disappearance of all tumor lesions (both index and non-index lesions with no new measurable/unmeasurable lesions). irPR: At least 30% reduction from baseline in the sum of the longest diameter (SLD) of all lesions). irSD: SLD of target and new measurable lesions neither irCR, irPR, or irPD. irPD: SLD of target and new measurable lesions increases greater than or equal to \[\>=\] 20%, confirmed by a repeat, consecutive observations at least 4 weeks from the date first documented. Number of participants with immune-related best overall response in each category (irCR, irPR, irSD, irPD) was reported.
Analysis population: Full analysis set (FAS) included all participants who have received at least 1 dose of study treatment. Here "Overall Number of Participants Analyzed" signifies those participants who were evaluable for this outcome measure.
Groups in this outcome
Primary Expansion Cohort: NSCLC, Post-platinum Doublet
Participants with non-small cell lung cancer (NSCLC), who had progressed after 1 line of platinum-containing doublet chemotherapy received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in primary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
Primary Expansion Cohort: NSCLC, First Line
Participants with non-small cell lung cancer (NSCLC), first line received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in primary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
Primary Expansion Cohort: Metastatic Breast Cancer
Participants with metastatic breast cancer received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in primary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
Primary Expansion Cohort: GC/GEJC Progressed
Participants with gastric and gastroesophageal cancer who progressed on or after first-line chemotherapy received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in primary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
Primary Expansion Cohort: GC/GEJC Non Progressed
Participants with gastric and gastroesophageal cancer who non-progressed on or after first-line chemotherapy received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in primary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
Secondary Expansion Cohort: Colorectal Cancer
Participants with colorectal cancer received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
Secondary Expansion Cohort: Castrate-resistant Prostate Cancer
Participants with castrate-resistant prostate cancer received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
Secondary Expansion Cohort: Adrenocortical Carcinoma
Participants with adrenocortical carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
Secondary Expansion Cohort: Melanoma
Participants with melanoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
Secondary Expansion Cohort: Mesothelioma
Participants with mesothelioma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
Secondary Expansion Cohort: Urothelial Carcinoma
Participants with urothelial carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
Secondary Expansion Cohort: Ovarian Cancer
Participants with ovarian carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
Secondary Expansion Cohort: Renal Cell Carcinoma (First Line)
Participants with Renal cell carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks as a first-line therapy in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
Secondary Expansion Cohort: Renal Cell Carcinoma (Second Line)
Participants with Renal cell carcinoma who failed 1 prior systemic first-line regimen received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks as a second line treatment in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
Efficacy Expansion Cohort: Ovarian Cancer
Participants with ovarian carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in efficacy expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
Efficacy Expansion Cohort: Urothelial Carcinoma
Participants with urothelial carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in efficacy expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
Efficacy Expansion Cohort: GC/GEJC, Third Line
Participants with gastric (GC) and gastroesophageal junction cancer (GEJC) who have failed both a first-line chemotherapy regimen and subsequent ramucirumab therapy, received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks as a third-line treatment in efficacy expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
Efficacy Expansion Cohort: HNSCC
Participants with head and neck squamous cell carcinoma (HNSCC) received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in efficacy expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
| Group | Source count |
|---|---|
| Primary Expansion Cohort: NSCLC, Post-platinum Doublet | 184 |
| Primary Expansion Cohort: NSCLC, First Line | 156 |
| Primary Expansion Cohort: Metastatic Breast Cancer | 168 |
| Primary Expansion Cohort: GC/GEJC Progressed | 60 |
| Primary Expansion Cohort: GC/GEJC Non Progressed | 90 |
| Secondary Expansion Cohort: Colorectal Cancer | 21 |
| Secondary Expansion Cohort: Castrate-resistant Prostate Cancer | 18 |
| Secondary Expansion Cohort: Adrenocortical Carcinoma | 50 |
| Secondary Expansion Cohort: Melanoma | 51 |
| Secondary Expansion Cohort: Mesothelioma | 53 |
| Secondary Expansion Cohort: Urothelial Carcinoma | 44 |
| Secondary Expansion Cohort: Ovarian Cancer | 125 |
| Secondary Expansion Cohort: Renal Cell Carcinoma (First Line) | 62 |
| Secondary Expansion Cohort: Renal Cell Carcinoma (Second Line) | 20 |
| Efficacy Expansion Cohort: Ovarian Cancer | 103 |
| Efficacy Expansion Cohort: Urothelial Carcinoma | 198 |
| Efficacy Expansion Cohort: GC/GEJC, Third Line | 132 |
| Efficacy Expansion Cohort: HNSCC | 153 |
Reported measurements
Immune-related Complete Response
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Primary Expansion Cohort: NSCLC, Post-platinum Doublet | 2 | Not reported | Not reported | Not reported | Not reported |
| Primary Expansion Cohort: NSCLC, First Line | 4 | Not reported | Not reported | Not reported | Not reported |
| Primary Expansion Cohort: Metastatic Breast Cancer | 1 | Not reported | Not reported | Not reported | Not reported |
| Primary Expansion Cohort: GC/GEJC Progressed | 0 | Not reported | Not reported | Not reported | Not reported |
| Primary Expansion Cohort: GC/GEJC Non Progressed | 2 | Not reported | Not reported | Not reported | Not reported |
| Secondary Expansion Cohort: Colorectal Cancer | 0 | Not reported | Not reported | Not reported | Not reported |
| Secondary Expansion Cohort: Castrate-resistant Prostate Cancer | 0 | Not reported | Not reported | Not reported | Not reported |
| Secondary Expansion Cohort: Adrenocortical Carcinoma | 0 | Not reported | Not reported | Not reported | Not reported |
| Secondary Expansion Cohort: Melanoma | 4 | Not reported | Not reported | Not reported | Not reported |
| Secondary Expansion Cohort: Mesothelioma | 1 | Not reported | Not reported | Not reported | Not reported |
| Secondary Expansion Cohort: Urothelial Carcinoma | 2 | Not reported | Not reported | Not reported | Not reported |
| Secondary Expansion Cohort: Ovarian Cancer | 1 | Not reported | Not reported | Not reported | Not reported |
| Secondary Expansion Cohort: Renal Cell Carcinoma (First Line) | 1 | Not reported | Not reported | Not reported | Not reported |
| Secondary Expansion Cohort: Renal Cell Carcinoma (Second Line) | 0 | Not reported | Not reported | Not reported | Not reported |
| Efficacy Expansion Cohort: Ovarian Cancer | 3 | Not reported | Not reported | Not reported | Not reported |
| Efficacy Expansion Cohort: Urothelial Carcinoma | 10 | Not reported | Not reported | Not reported | Not reported |
| Efficacy Expansion Cohort: GC/GEJC, Third Line | 1 | Not reported | Not reported | Not reported | Not reported |
| Efficacy Expansion Cohort: HNSCC | 6 | Not reported | Not reported | Not reported | Not reported |
Immune-related Partial Response
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Primary Expansion Cohort: NSCLC, Post-platinum Doublet | 26 | Not reported | Not reported | Not reported | Not reported |
| Primary Expansion Cohort: NSCLC, First Line | 31 | Not reported | Not reported | Not reported | Not reported |
| Primary Expansion Cohort: Metastatic Breast Cancer | 6 | Not reported | Not reported | Not reported | Not reported |
| Primary Expansion Cohort: GC/GEJC Progressed | 5 | Not reported | Not reported | Not reported | Not reported |
| Primary Expansion Cohort: GC/GEJC Non Progressed | 4 | Not reported | Not reported | Not reported | Not reported |
| Secondary Expansion Cohort: Colorectal Cancer | 0 | Not reported | Not reported | Not reported | Not reported |
| Secondary Expansion Cohort: Castrate-resistant Prostate Cancer | 0 | Not reported | Not reported | Not reported | Not reported |
| Secondary Expansion Cohort: Adrenocortical Carcinoma | 3 | Not reported | Not reported | Not reported | Not reported |
| Secondary Expansion Cohort: Melanoma | 7 | Not reported | Not reported | Not reported | Not reported |
| Secondary Expansion Cohort: Mesothelioma | 4 | Not reported | Not reported | Not reported | Not reported |
| Secondary Expansion Cohort: Urothelial Carcinoma | 5 | Not reported | Not reported | Not reported | Not reported |
| Secondary Expansion Cohort: Ovarian Cancer | 15 | Not reported | Not reported | Not reported | Not reported |
| Secondary Expansion Cohort: Renal Cell Carcinoma (First Line) | 10 | Not reported | Not reported | Not reported | Not reported |
| Secondary Expansion Cohort: Renal Cell Carcinoma (Second Line) | 2 | Not reported | Not reported | Not reported | Not reported |
| Efficacy Expansion Cohort: Ovarian Cancer | 4 | Not reported | Not reported | Not reported | Not reported |
| Efficacy Expansion Cohort: Urothelial Carcinoma | 24 | Not reported | Not reported | Not reported | Not reported |
| Efficacy Expansion Cohort: GC/GEJC, Third Line | 7 | Not reported | Not reported | Not reported | Not reported |
| Efficacy Expansion Cohort: HNSCC | 15 | Not reported | Not reported | Not reported | Not reported |
Immune-related Stable Disease
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Primary Expansion Cohort: NSCLC, Post-platinum Doublet | 80 | Not reported | Not reported | Not reported | Not reported |
| Primary Expansion Cohort: NSCLC, First Line | 78 | Not reported | Not reported | Not reported | Not reported |
| Primary Expansion Cohort: Metastatic Breast Cancer | 60 | Not reported | Not reported | Not reported | Not reported |
| Primary Expansion Cohort: GC/GEJC Progressed | 20 | Not reported | Not reported | Not reported | Not reported |
| Primary Expansion Cohort: GC/GEJC Non Progressed | 53 | Not reported | Not reported | Not reported | Not reported |
| Secondary Expansion Cohort: Colorectal Cancer | 9 | Not reported | Not reported | Not reported | Not reported |
| Secondary Expansion Cohort: Castrate-resistant Prostate Cancer | 3 | Not reported | Not reported | Not reported | Not reported |
| Secondary Expansion Cohort: Adrenocortical Carcinoma | 26 | Not reported | Not reported | Not reported | Not reported |
| Secondary Expansion Cohort: Melanoma | 20 | Not reported | Not reported | Not reported | Not reported |
| Secondary Expansion Cohort: Mesothelioma | 31 | Not reported | Not reported | Not reported | Not reported |
| Secondary Expansion Cohort: Urothelial Carcinoma | 21 | Not reported | Not reported | Not reported | Not reported |
| Secondary Expansion Cohort: Ovarian Cancer | 61 | Not reported | Not reported | Not reported | Not reported |
| Secondary Expansion Cohort: Renal Cell Carcinoma (First Line) | 40 | Not reported | Not reported | Not reported | Not reported |
| Secondary Expansion Cohort: Renal Cell Carcinoma (Second Line) | 15 | Not reported | Not reported | Not reported | Not reported |
| Efficacy Expansion Cohort: Ovarian Cancer | 44 | Not reported | Not reported | Not reported | Not reported |
| Efficacy Expansion Cohort: Urothelial Carcinoma | 61 | Not reported | Not reported | Not reported | Not reported |
| Efficacy Expansion Cohort: GC/GEJC, Third Line | 29 | Not reported | Not reported | Not reported | Not reported |
| Efficacy Expansion Cohort: HNSCC | 61 | Not reported | Not reported | Not reported | Not reported |
Immune-related Progressive Disease
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Primary Expansion Cohort: NSCLC, Post-platinum Doublet | 36 | Not reported | Not reported | Not reported | Not reported |
| Primary Expansion Cohort: NSCLC, First Line | 21 | Not reported | Not reported | Not reported | Not reported |
| Primary Expansion Cohort: Metastatic Breast Cancer | 69 | Not reported | Not reported | Not reported | Not reported |
| Primary Expansion Cohort: GC/GEJC Progressed | 0 | Not reported | Not reported | Not reported | Not reported |
| Primary Expansion Cohort: GC/GEJC Non Progressed | 0 | Not reported | Not reported | Not reported | Not reported |
| Secondary Expansion Cohort: Colorectal Cancer | 5 | Not reported | Not reported | Not reported | Not reported |
| Secondary Expansion Cohort: Castrate-resistant Prostate Cancer | 1 | Not reported | Not reported | Not reported | Not reported |
| Secondary Expansion Cohort: Adrenocortical Carcinoma | 14 | Not reported | Not reported | Not reported | Not reported |
| Secondary Expansion Cohort: Melanoma | 11 | Not reported | Not reported | Not reported | Not reported |
| Secondary Expansion Cohort: Mesothelioma | 10 | Not reported | Not reported | Not reported | Not reported |
| Secondary Expansion Cohort: Urothelial Carcinoma | 10 | Not reported | Not reported | Not reported | Not reported |
| Secondary Expansion Cohort: Ovarian Cancer | 27 | Not reported | Not reported | Not reported | Not reported |
| Secondary Expansion Cohort: Renal Cell Carcinoma (First Line) | 6 | Not reported | Not reported | Not reported | Not reported |
| Secondary Expansion Cohort: Renal Cell Carcinoma (Second Line) | 1 | Not reported | Not reported | Not reported | Not reported |
| Efficacy Expansion Cohort: Ovarian Cancer | 33 | Not reported | Not reported | Not reported | Not reported |
| Efficacy Expansion Cohort: Urothelial Carcinoma | 62 | Not reported | Not reported | Not reported | Not reported |
| Efficacy Expansion Cohort: GC/GEJC, Third Line | 62 | Not reported | Not reported | Not reported | Not reported |
| Efficacy Expansion Cohort: HNSCC | 44 | Not reported | Not reported | Not reported | Not reported |
Not Evaluable
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Primary Expansion Cohort: NSCLC, Post-platinum Doublet | 40 | Not reported | Not reported | Not reported | Not reported |
| Primary Expansion Cohort: NSCLC, First Line | 22 | Not reported | Not reported | Not reported | Not reported |
| Primary Expansion Cohort: Metastatic Breast Cancer | 32 | Not reported | Not reported | Not reported | Not reported |
| Primary Expansion Cohort: GC/GEJC Progressed | 35 | Not reported | Not reported | Not reported | Not reported |
| Primary Expansion Cohort: GC/GEJC Non Progressed | 31 | Not reported | Not reported | Not reported | Not reported |
| Secondary Expansion Cohort: Colorectal Cancer | 7 | Not reported | Not reported | Not reported | Not reported |
| Secondary Expansion Cohort: Castrate-resistant Prostate Cancer | 14 | Not reported | Not reported | Not reported | Not reported |
| Secondary Expansion Cohort: Adrenocortical Carcinoma | 7 | Not reported | Not reported | Not reported | Not reported |
| Secondary Expansion Cohort: Melanoma | 9 | Not reported | Not reported | Not reported | Not reported |
| Secondary Expansion Cohort: Mesothelioma | 7 | Not reported | Not reported | Not reported | Not reported |
| Secondary Expansion Cohort: Urothelial Carcinoma | 6 | Not reported | Not reported | Not reported | Not reported |
| Secondary Expansion Cohort: Ovarian Cancer | 21 | Not reported | Not reported | Not reported | Not reported |
| Secondary Expansion Cohort: Renal Cell Carcinoma (First Line) | 5 | Not reported | Not reported | Not reported | Not reported |
| Secondary Expansion Cohort: Renal Cell Carcinoma (Second Line) | 2 | Not reported | Not reported | Not reported | Not reported |
| Efficacy Expansion Cohort: Ovarian Cancer | 19 | Not reported | Not reported | Not reported | Not reported |
| Efficacy Expansion Cohort: Urothelial Carcinoma | 41 | Not reported | Not reported | Not reported | Not reported |
| Efficacy Expansion Cohort: GC/GEJC, Third Line | 33 | Not reported | Not reported | Not reported | Not reported |
| Efficacy Expansion Cohort: HNSCC | 27 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- calculate Pct
- false
- classes
- categories
- measurements
- group Id
- OG000
- value
- 2
- group Id
- OG001
- value
- 4
- group Id
- OG002
- value
- 1
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 2
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- group Id
- OG007
- value
- 0
- group Id
- OG008
- value
- 4
- group Id
- OG009
- value
- 1
- group Id
- OG010
- value
- 2
- group Id
- OG011
- value
- 1
- title
- Immune-related Complete Response
- categories
- measurements
- group Id
- OG000
- value
- 26
- group Id
- OG001
- value
- 31
- group Id
- OG002
- value
- 6
- group Id
- OG003
- value
- 5
- group Id
- OG004
- value
- 4
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- group Id
- OG007
- value
- 3
- group Id
- OG008
- value
- 7
- group Id
- OG009
- value
- 4
- group Id
- OG010
- value
- 5
- group Id
- OG011
- value
- 15
- title
- Immune-related Partial Response
- categories
- measurements
- group Id
- OG000
- value
- 80
- group Id
- OG001
- value
- 78
- group Id
- OG002
- value
- 60
- group Id
- OG003
- value
- 20
- group Id
- OG004
- value
- 53
- group Id
- OG005
- value
- 9
- group Id
- OG006
- value
- 3
- group Id
- OG007
- value
- 26
- group Id
- OG008
- value
- 20
- group Id
- OG009
- value
- 31
- group Id
- OG010
- value
- 21
- group Id
- OG011
- value
- 61
- title
- Immune-related Stable Disease
- categories
- measurements
- group Id
- OG000
- value
- 36
- group Id
- OG001
- value
- 21
- group Id
- OG002
- value
- 69
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 5
- group Id
- OG006
- value
- 1
- group Id
- OG007
- value
- 14
- group Id
- OG008
- value
- 11
- group Id
- OG009
- value
- 10
- group Id
- OG010
- value
- 10
- group Id
- OG011
- value
- 27
- title
- Immune-related Progressive Disease
- categories
- measurements
- group Id
- OG000
- value
- 40
- group Id
- OG001
- value
- 22
- group Id
- OG002
- value
- 32
- group Id
- OG003
- value
- 35
- group Id
- OG004
- value
- 31
- group Id
- OG005
- value
- 7
- group Id
- OG006
- value
- 14
- group Id
- OG007
- value
- 7
- group Id
- OG008
- value
- 9
- group Id
- OG009
- value
- 7
- group Id
- OG010
- value
- 6
- group Id
- OG011
- value
- 21
- title
- Not Evaluable
- denoms
- counts
- group Id
- OG000
- value
- 184
- group Id
- OG001
- value
- 156
- group Id
- OG002
- value
- 168
- group Id
- OG003
- value
- 60
- group Id
- OG004
- value
- 90
- group Id
- OG005
- value
- 21
- group Id
- OG006
- value
- 18
- group Id
- OG007
- value
- 50
- group Id
- OG008
- value
- 51
- group Id
- OG009
- value
- 53
- group Id
- OG010
- value
- 44
- group Id
- OG011
- value
- 125
- units
- Participants
- description
- irBOR defined as best response of any of immune related complete response (irCR), immune related partial response (irPR), immune related stable disease (irSD) and immune related progressive disease (irPD) recorded from baseline until immune related disease progression and determined according to modified irRC per investigator assessment. irCR: Complete disappearance of all tumor lesions (both index and non-index lesions with no new measurable/unmeasurable lesions). irPR: At least 30% reduction from baseline in the sum of the longest diameter (SLD) of all lesions). irSD: SLD of target and new measurable lesions neither irCR, irPR, or irPD. irPD: SLD of target and new measurable lesions increases greater than or equal to \[\>=\] 20%, confirmed by a repeat, consecutive observations at least 4 weeks from the date first documented. Number of participants with immune-related best overall response in each category (irCR, irPR, irSD, irPD) was reported.
- groups
- description
- Participants with non-small cell lung cancer (NSCLC), who had progressed after 1 line of platinum-containing doublet chemotherapy received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in primary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
- id
- OG000
- title
- Primary Expansion Cohort: NSCLC, Post-platinum Doublet
- description
- Participants with non-small cell lung cancer (NSCLC), first line received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in primary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
- id
- OG001
- title
- Primary Expansion Cohort: NSCLC, First Line
- description
- Participants with metastatic breast cancer received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in primary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
- id
- OG002
- title
- Primary Expansion Cohort: Metastatic Breast Cancer
- description
- Participants with gastric and gastroesophageal cancer who progressed on or after first-line chemotherapy received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in primary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
- id
- OG003
- title
- Primary Expansion Cohort: GC/GEJC Progressed
- description
- Participants with gastric and gastroesophageal cancer who non-progressed on or after first-line chemotherapy received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in primary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
- id
- OG004
- title
- Primary Expansion Cohort: GC/GEJC Non Progressed
- description
- Participants with colorectal cancer received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
- id
- OG005
- title
- Secondary Expansion Cohort: Colorectal Cancer
- description
- Participants with castrate-resistant prostate cancer received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
- id
- OG006
- title
- Secondary Expansion Cohort: Castrate-resistant Prostate Cancer
- description
- Participants with adrenocortical carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
- id
- OG007
- title
- Secondary Expansion Cohort: Adrenocortical Carcinoma
- description
- Participants with melanoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
- id
- OG008
- title
- Secondary Expansion Cohort: Melanoma
- description
- Participants with mesothelioma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
- id
- OG009
- title
- Secondary Expansion Cohort: Mesothelioma
- description
- Participants with urothelial carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
- id
- OG010
- title
- Secondary Expansion Cohort: Urothelial Carcinoma
- description
- Participants with ovarian carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
- id
- OG011
- title
- Secondary Expansion Cohort: Ovarian Cancer
- param Type
- COUNT_OF_PARTICIPANTS
- population Description
- Full analysis set (FAS) included all participants who have received at least 1 dose of study treatment. Here "Overall Number of Participants Analyzed" signifies those participants who were evaluable for this outcome measure.
- reporting Status
- POSTED
- time Frame
- Dose Expansion: Baseline up to Day 2023
- title
- Dose Expansion Cohort: Number of Participants With Immune Related Best Overall Response (irBOR) According to Modified Immune-Related Response Criteria (irRC)
- type
- SECONDARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice